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Dear Editor 
Corticosteroid treatment of asthma: 
now at the crossroads 
I read with interest the observation of Seale and Donnelly 
(1) on the relative systemic activity of fluticasone proprio- 
nate (FP) and budesonide (BUD). This is based on studies 
in healthy volunteers. In a previous meta-analysis of studies 
performed in patients with asthma (2), I noted that if 
anything the effect was the opposite of the one they 
describe. 
In order to address this apparent contradiction, I per- 
formed an analysis to consolidate the large volume of 
literature comparing the systematic effects on the HPA axis 
of FP versus BUD in healthy volunteers and asthmatics. To 
test the hypothesis that observations of systemic effects in 
volunteers may not predict the outcome in patients, I 
carried out a review of all studies of FP and BUD published 
to date which measured effects on cortisol(3-25). To avoid 
bias, data were selected only where both FP and BUD were 
compared in the same study. Use of plasma and urine 
samples and measurements of both AUC cortisol and AM 
cortisol, compared either to baseline or placebo, were 
reported. Where multiple measures were reported in a 
study, urine or plasma area under the curve and change 
from placebo was selected in preference to the less sensitive 
morning plasma cortisol data. 
For the purpose of the analysis, the effect of any dose of 
FP or BUD on cortisol levels was assessed by using the 
residual level of cortisol remaining at the end of treatment 
expressed as a percentage of baseline (or placebo response). 
BUD and FP were then compared within each study using 
the ratio of the respective residual percentages; ratios 
greater than 1 indicate FP suppression greater than BUD. 
Data were used only from the highest dose pair of FP and 
BUD in any study. Table 1 shows the resulting doses 
compared and effect on co&sol levels together with their 
weighted (by group size) means. 
At approximately equal doses, these results confirm that 
in healthy volunteers, FP gives rise to higher levels of 
cortisol suppression than BUD (BUD/FP ratio=3.3). How- 
ever in asthmatic patients, FP and BUD result in equal 
effects on the HPA axis (BUD/FP ratio= 1.0). 
These data suggest a difference in the relative systemic 
exposure of healthy volunteers and asthmatic patients to 
FP and BUD. This is consistent with pharmacokinetic data 
which have shown that volunteers have two-fold higher FP 
levels than patients with asthma (26). From these pharma- 
cokinetic data, one could infer a reduction in lung absorp- 
tion in asthmatic patients which, given the negligible oral 
bioavailability of FP, would lead to a low systemic expo- 
sure to FP but not BUD as was observed in the current 
analysis. I conclude that studies of systemic exposure in 
healthy volunteers may not reflect the clinical outcome in 
patients. However, specifically designed studies should be 
used to test this hypothesis. 
C. HALLETT, B.Sc., CSTAT. 
Consultant Statistician to Glaxo Wellcome R and D., 
14, Boleyn Avenue, 
Ewell, Epsom, 
Surrey, KT37 2QH, U.K. 
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TABLE 1. Effect of FP and BUD on cortisol changes in volunteers and patients 
Reference 
n Cortisol Cortisol BUD/FP 
(per remaining remaining cortisol 
FP BUD treatment (% of baseline) (% of baseline) remaining 
(mcg day - ‘) (mcg day - ‘) grow) FP BUD ratio 
Volunteer studies 
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Dogterom et al. (4) 
Donnelly et al. (5) 
Grahnen et al. (6) 
Grahnen et al. (7) 
Lonnebo et al. (8) 
Wales et al. (9) 
2000 2000 21 
2000 2000 21 
2000 3200 28 
2000 1600 21 
1000 800 25 
2000 1600 24 
4000 4000 8 
16 
16 
14 
72 
45 
14 
73 4.6 
73 4.6 
31 4.4 
53 3.8 
84 1.2 
66 1.5 
57 4.1 
Weighted mean ratio 3.3 
Patient studies 
Agertoft et al. (10) 
Agertoft et al. (11) 
Ayres et al. (12) 
Pickering et al. (13) 
Clark et al. (14) 
Clark et al. (15) 
Clark et al. (16) 
Connolly et al. (17) 
Derom et al. (18) 
Hoekx et al. (19) 
Langdon et al. (20) 
Langdon et al. (21) 
Lipworth et al. (22) 
Ringdal et al. (23) 
Ringdal et al. (24) 
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